New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab

Marco Lima, Igor Koralnik

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Over the past three decades, progressive multifocal leukoencephalopathy (PML) evolved from being a clinical rarity to become an important cause of neurological complications in acquired immunodeficiency syndrome (AIDS) patients. Recently this disease unexpectedly occurred in patients receiving the novel immunomodulatory medication natalizumab. These changes in the epidemiology of PML also brought new questions with regard to the pathogenesis of this disease. The authors review the current challenges in the diagnosis and management of patients with PML, based on the recent advances in the understanding of the JC virus biology and discuss potential methods to monitor disease evolution and predict outcome.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalJournal of neurovirology
Volume11
Issue numberSUPPL. 3
DOIs
StatePublished - 2005

Keywords

  • HAART
  • HIV
  • JC virus
  • Natalizumab
  • Progressive multifocal leukoencephalopathy (PML)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Fingerprint Dive into the research topics of 'New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab'. Together they form a unique fingerprint.

Cite this